Abstract
The kinetics of oxcarbazepine (OXC) and its active metabolite 10-hydroxy-carbazepine (10-OH-CZ) after a single oral OXC dose (600 mg) were compared in healthy control subjects and in epileptic patients treated with phenobarbitone or sodium valproate (n = 8 in each group). In all groups, serum 10-OH-CZ concentrations were much higher than those of the parent drug. In patients on valproate, the kinetics of OXC and 10-OH-CZ did not differ significantly from those observed in controls. In patients on phenobarbitone, AUC values of both OXC and 10-OH-CZ were lower than in controls (2.9 +/- 0.4 vs 5.1 +/- 0.7 microg ml(-1) h and 89 +/- 7 vs 119 +/- 10 microg ml(-1) h respectively, means +/- s.e. mean, P < 0.05), whereas 10-OH-CZ half-lives were only marginally shorter (17 +/- 1 h vs 20 +/- 2 h, NS). These data indicate that the biotransformation of OXC and 10-OH-CZ may be accelerated by concomitant treatment with phenobarbitone but that the magnitude of this effect is unlikely to be of great clinical significance.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Binnie C. D., van Emde Boas W., Kasteleijn-Nolste-Trenite D. G., de Korte R. A., Meijer J. W., Meinardi H., Miller A. A., Overweg J., Peck A. W., van Wieringen A. Acute effects of lamotrigine (BW430C) in persons with epilepsy. Epilepsia. 1986 May-Jun;27(3):248–254. doi: 10.1111/j.1528-1157.1986.tb03536.x. [DOI] [PubMed] [Google Scholar]
- Brodie M. J. Drug interactions in epilepsy. Epilepsia. 1992;33 (Suppl 1):S13–S22. doi: 10.1111/j.1528-1157.1992.tb05896.x. [DOI] [PubMed] [Google Scholar]
- Dickinson R. G., Hooper W. D., Dunstan P. R., Eadie M. J. First dose and steady-state pharmacokinetics of oxcarbazepine and its 10-hydroxy metabolite. Eur J Clin Pharmacol. 1989;37(1):69–74. doi: 10.1007/BF00609428. [DOI] [PubMed] [Google Scholar]
- Elyas A. A., Goldberg V. D., Patsalos P. N. Simple and rapid micro-analytical high-performance liquid chromatographic technique for the assay of oxcarbazepine and its primary active metabolite 10-hydroxycarbazepine. J Chromatogr. 1990 Jun 29;528(2):473–479. doi: 10.1016/s0378-4347(00)82406-8. [DOI] [PubMed] [Google Scholar]
- Grant S. M., Faulds D. Oxcarbazepine. A review of its pharmacology and therapeutic potential in epilepsy, trigeminal neuralgia and affective disorders. Drugs. 1992 Jun;43(6):873–888. doi: 10.2165/00003495-199243060-00007. [DOI] [PubMed] [Google Scholar]
- Kumps A., Wurth C. Oxcarbazepine disposition: preliminary observations in patients. Biopharm Drug Dispos. 1990 May-Jun;11(4):365–370. doi: 10.1002/bdd.2510110405. [DOI] [PubMed] [Google Scholar]
- Pisani F., Caputo M., Fazio A., Oteri G., Russo M., Spina E., Perucca E., Bertilsson L. Interaction of carbamazepine-10,11-epoxide, an active metabolite of carbamazepine, with valproate: a pharmacokinetic study. Epilepsia. 1990 May-Jun;31(3):339–342. doi: 10.1111/j.1528-1157.1990.tb05385.x. [DOI] [PubMed] [Google Scholar]
- Pisani F., Perucca E., Di Perri R. Clinically relevant anti-epileptic drug interactions. J Int Med Res. 1990 Jan-Feb;18(1):1–15. doi: 10.1177/030006059001800102. [DOI] [PubMed] [Google Scholar]
- Tartara A., Galimberti C. A., Manni R., Parietti L., Zucca C., Baasch H., Caresia L., Mück W., Barzaghi N., Gatti G. Differential effects of valproic acid and enzyme-inducing anticonvulsants on nimodipine pharmacokinetics in epileptic patients. Br J Clin Pharmacol. 1991 Sep;32(3):335–340. doi: 10.1111/j.1365-2125.1991.tb03908.x. [DOI] [PMC free article] [PubMed] [Google Scholar]